Breaking News
November 21, 2017 - Seven body organs you can live without
November 21, 2017 - Simple test could help predict best treatment for cystic fibrosis patients
November 21, 2017 - Diabetes patients’ immune system can regulate insulin production
November 21, 2017 - Simple mirror technique boosts the performance of diSPIM, study says
November 21, 2017 - FDA raids Florida stores that consumers use to buy drugs from Canada
November 21, 2017 - FDA Alert: Limbrel Capsules by Primus Pharmaceuticals: FDA Advisory
November 21, 2017 - Exploring the genetics of glaucoma and retinal development
November 21, 2017 - Study finds sensors to detect biomarkers
November 21, 2017 - Researchers develop simple test to predict T2D remission after bariatric surgery
November 21, 2017 - Penn researchers find evidence of new malaria species in wild bonobos
November 21, 2017 - Review examines effectiveness of lipid-based products to treat dry eye disease
November 21, 2017 - Pioneering research project aims to develop better diagnostic tests for NAFLD
November 21, 2017 - The Best and Worst Ways to Say ‘I Love You’
November 21, 2017 - Even Partial Breast-Feeding for First Few Months Lowers SIDS Risk: MedlinePlus Health News
November 21, 2017 - Researchers identify protein that plays key role in diabetic blindness
November 21, 2017 - Sensors for identifying biomarkers could help detect myriad of diseases at early stages
November 21, 2017 - ‘Chemo brain’ may start as tumors form and develop, suggests study
November 21, 2017 - Scientists develop new method to study Creutzfeldt-Jakob disease in the lab
November 21, 2017 - Researchers identify previously unknown breast cell types
November 21, 2017 - Probing living cells with AFM
November 21, 2017 - Streamlined method for using CGM helps patients with diabetes maintain safe, stable glucose levels
November 21, 2017 - Even Advanced Breast Cancer Patients Gain From Exercise: MedlinePlus Health News
November 21, 2017 - Study in mice finds dietary levels of genistein may adversely affect female fertility
November 21, 2017 - Disordered eating has detrimental effects to long-term health of young adults, study finds
November 21, 2017 - Babies know more than we think they do find researchers
November 21, 2017 - New technique may reveal clues about role of centromeres in Down syndrome, other birth defects
November 21, 2017 - IUD May Lower Cervical Cancer Risk: MedlinePlus Health News
November 21, 2017 - U.S. preemie birth rates rise two years in a row
November 21, 2017 - Heart rate variability measured by electrocardiogram can help differentiate bipolar from major depression
November 21, 2017 - $10 million gift creates new center at Northwestern University to study effects of environment on genes
November 21, 2017 - Uncontrolled lung diseases could lead to costly A&E visits and hospital stays
November 21, 2017 - New study explores patients’ and family members’ views on overlapping surgeries
November 21, 2017 - KNAUER celebrates 55th anniversary and awards science prize
November 21, 2017 - Researchers find new way to boost cancer-destroying ability of T-cells
November 21, 2017 - Maintaining adequate vitamin D may help prevent onset of inflammatory diseases
November 21, 2017 - What NPs Can Do in the Opioid Crisis
November 21, 2017 - Gun Injuries Getting More Severe, Experts Say: MedlinePlus Health News
November 21, 2017 - That music playing in your head is a real conundrum for scientists
November 21, 2017 - Researcher awarded $1.5 million to study role of tumor necrosis factor in IBD
November 21, 2017 - Digital pills can help track opioid use patterns
November 21, 2017 - UZH leads Europe’s largest research on aging
November 21, 2017 - Experts endorse recommendations for restrictive blood transfusions
November 21, 2017 - New Hemophilia A Treatment, Hemlibra (Emicizumab-kxwh), Stems Bleeding Episodes
November 21, 2017 - Shining a light on the nervous system to thwart disease
November 21, 2017 - Use of Prostate Health Index cuts down need for uncomfortable biopsies
November 21, 2017 - Drugstore pain pills as effective as opioids in ER patients
November 21, 2017 - Experts explain why lead found in fidget spinners is no idle threat
November 21, 2017 - Over-the-counter decongestant found to be effective inhibitor of tumor stroma
November 21, 2017 - Anticholinergic Cognitive Burden Scale shows dose-response relationship with adverse outcomes
November 21, 2017 - Non-vitamin K antagonist oral anticoagulants linked to reduced kidney risks
November 21, 2017 - New technique holds promise to screen cancer cells for drug susceptibility
November 21, 2017 - AstraZeneca wins US approval for lymphoma drug
November 21, 2017 - Mother’s diet can protect nursing newborns against food allergies, research shows
November 21, 2017 - Cystic fibrosis patients have more good and bad bacteria in their lungs, study finds
November 21, 2017 - Patient-centered medical home model effective at improving chronic disease outcomes
November 21, 2017 - Enterovirus vaccine protects against virus-induced diabetes in mouse model
November 20, 2017 - First-of-its-kind study combines smoking cessation with personalized medicine
November 20, 2017 - FDA Approves Sutent (sunitinib malate) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
November 20, 2017 - Researchers produce the first draft cell atlas of the small intestine
November 20, 2017 - Study explores feasibility of mainstreaming genetic counseling for ovarian cancer
November 20, 2017 - AAP and The Obesity Society jointly address weight stigma in childhood obesity
November 20, 2017 - Researchers identify three specific molecules that accurately indicate pre-diabetes
November 20, 2017 - Study estimates health care costs, injuries, and deaths due to motorcycle accidents
November 20, 2017 - Face It: Drinking, Smoking Takes Toll on Looks
November 20, 2017 - Women have lower tolerance to alcohol following gastric sleeve surgery, study finds
November 20, 2017 - Salt, inflammation and hypertension
November 20, 2017 - Electrochemistry method provides easy access to important classes of compounds
November 20, 2017 - Cancer drugs may offer new way to control high blood pressure
November 20, 2017 - Small molecules in saliva may offer clues to diagnose and predict duration of concussions
November 20, 2017 - New poll demonstrates challenge of finding childcare options that meet parent’s safety criteria
November 20, 2017 - Canadians root for an underdog U.S. health policy idea
November 20, 2017 - KAIST researchers identify principles of gene network for colon tumorigenesis
November 20, 2017 - Pregnant mother in a coma wakes three months after delivery
November 20, 2017 - VTT researcher develops disposable optical test substrate for microbial detection
November 20, 2017 - Benzodiazepines linked to increased risk of death among Alzheimer’s disease patients
November 20, 2017 - Women are advised that sleeping on their side could reduce stillbirth risk
November 20, 2017 - The skinny on lipid immunology
November 20, 2017 - Study sheds light on changes in young people’s sexual practices
November 20, 2017 - Study highlights need for early identification, treatment of PTSD in cancer survivors
November 20, 2017 - FDA approves remote programming feature for Nucleus Cochlear Implant System via telemedicine
FDA Approves Cinvanti (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)

FDA Approves Cinvanti (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)

image_pdfDownload PDFimage_print

FDA Approves Cinvanti (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV)

SAN DIEGO–(BUSINESS WIRE)–Nov. 9, 2017– Heron Therapeutics, Inc. (Nasdaq: HRTX) (the Company or Heron), a commercial-stage biotechnology company focused on developing novel, best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has approved Cinvanti (aprepitant) injectable emulsion, for intravenous infusion. Cinvanti is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin and nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Cinvanti is the first and only polysorbate 80-free, intravenous formulation of an NK1 receptor antagonist indicated for the prevention of acute and delayed CINV. Cinvanti is the first intravenous formulation to directly deliver aprepitant, the active ingredient in Emend® capsules. Aprepitant (including its prodrug, fosaprepitant) is the only single-agent NK1 receptor antagonist to significantly reduce CINV in both the acute phase (0 – 24 hours after chemotherapy) and the delayed phase (24 – 120 hours after chemotherapy).i,ii Cinvanti does not contain polysorbate 80 or any other synthetic surfactant. Pharmaceutical formulations containing polysorbate 80 have been linked to hypersensitivity reactions, including anaphylaxis and irritation of blood vessels resulting in infusion-site pain.ii,iii,iv

Cinvanti was approved based on data demonstrating the bioequivalence of Cinvanti to Emend IV® (fosaprepitant), supporting its efficacy for the prevention of acute and delayed CINV following HEC and MEC.

Results from 2 pivotal randomized, cross-over bioequivalence studies of Cinvanti and Emend IV showed subjects receiving Cinvanti reported fewer adverse events than those receiving Emend IV, including substantially fewer infusion-site reactions.v

“CINV remains a high unmet medical need in the oncology community, and 5 full days of CINV coverage continues to be our goal. NK1 receptor antagonists are recommended for routine use with HEC and are a recommended option with MEC. Despite this, NK1 receptor antagonists are underutilized in CINV. This provides a large opportunity for Cinvanti to help more patients avoid CINV and adhere to their chemotherapy regimens,” said Jeffrey F. Patton, M.D., Chief Executive Officer of Tennessee Oncology.

“Aprepitant has long been the standard in the NK1 class and it remains the only single-agent NK1 with proven efficacy in preventing CINV in both the acute and delayed phases in HEC and MEC. Because Cinvanti is a novel, polysorbate 80-free IV formulation of aprepitant, it enables physicians to provide patients with standard-of-care efficacy without the potential risk of polysorbate 80-related adverse events, such as infusion-site reactions,” said Rudolph M. Navari, M.D., Ph.D., University of Alabama, Birmingham School of Medicine, Director, Cancer Care Program, Division of Hematology Oncology.

“Since both Cinvanti and SUSTOL have been shown to significantly reduce CINV in both the acute and delayed phase, by complementary mechanisms, they are an excellent strategic and operational fit for the Heron commercial team. The commercial team is ready to launch Cinvanti in January of next year,” said Barry D. Quart, Pharm.D., Chief Executive Officer of Heron. “To obtain FDA approval for a second product in just over a year is a significant achievement for Heron, and we remain on-track with our third important product, HTX-011, which we expect to file for FDA review in 2018.”

About Cinvanti (aprepitant) injectable emulsion

Cinvanti is an intravenous formulation of aprepitant, an NK1 receptor antagonist for the prevention of CINV. Cinvanti is used in combination with a 5-HT3 receptor antagonist and dexamethasone. Heron developed Cinvanti, a proprietary novel lipid emulsion formulation of aprepitant, to overcome the low water solubility of aprepitant without polysorbate 80 or other synthetic surfactants, with the goal to reduce the risk for infusion-site reactions and hypersensitivity reactions that are reported with Emend IV.

Important Safety Information for Cinvanti

Cinvanti is contraindicated in patients with hypersensitivity to any of the components of Cinvanti. Serious hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported with fosaprepitant, a prodrug of aprepitant, and with oral aprepitant. Symptoms including flushing, erythema, dyspnea, hypotension and syncope have been reported. If symptoms occur, discontinue Cinvanti. Do not reinstate if symptoms occur with first-time use.

Use of pimozide with Cinvanti is contraindicated due to the risk of significantly increased plasma concentrations of pimozide, potentially resulting in prolongation of the QT interval, a known adverse reaction of pimozide.

Use of Cinvanti may result in clinically significant CYP3A4 Drug Interactions. Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Use with other drugs that are CYP3A4 substrates may result in increased plasma concentration of the concomitant drug. Use of Cinvanti with strong or moderate CYP3A4 inhibitors (e.g., ketoconazole, diltiazem) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to Cinvanti. Use of Cinvanti with strong CYP3A4 inducers (e.g., rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of aprepitant.

Co-administration of Cinvanti with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week period, particularly at 7 to 10 days, following initiation of Cinvanti with each chemotherapy cycle.
The efficacy of hormonal contraceptives may be reduced during administration of and for 28 days following the last dose of Cinvanti. Advise patients to use effective alternative or back-up methods of non-hormonal contraception during treatment with Cinvanti and for 1 month following administration of Cinvanti or oral aprepitant, whichever is administered last.

Avoid use of Cinvanti in pregnant women as alcohol is an inactive ingredient for Cinvanti. There is no safe level of alcohol exposure in pregnancy.

No dosage adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9). There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score greater than 9). Additional monitoring for adverse reactions in these patients may be warranted when Cinvanti is administered.

In general, use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal or cardiac function and concomitant disease or other drug therapy.

The most common adverse reactions with the 3-day oral aprepitant regimen in conjunction with MEC (≥1% and greater than standard therapy) were fatigue and eructation.
The most common adverse reactions with the single-dose intravenous fosaprepitant regimen in conjunction with HEC were generally similar to that seen in prior HEC studies with oral aprepitant. In addition, infusion site reactions (3%) occurred.

The most common adverse reactions with a single-dose of Cinvanti (≥2%) were headache and fatigue.

About Chemotherapy-Induced Nausea and Vomiting (CINV)

While chemotherapy is one of the most effective and commonly used therapies to help patients fight cancer, it is accompanied by debilitating side effects, including varying degrees of nausea and vomiting, often attributed as a leading cause of premature discontinuation of cancer treatment. The goal of antiemetic therapy is to prevent CINV in both the acute phase (0 – 24 hours after chemotherapy) and delayed phase (24 – 120 hours after chemotherapy). The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) have categorized chemotherapy regimens based on the degree to which they cause nausea and vomiting: low emetogenic chemotherapy (LEC); moderately emetogenic chemotherapy (MEC); and highly emetogenic chemotherapy (HEC).

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. For more information, visit www.herontx.com.

Forward-Looking Statements

This news release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, those associated with: the timing of the commercial launch of Cinvanti; postmarketing safety information for SUSTOL and Cinvanti; the potential market opportunity for Cinvanti; whether the HTX-011 Phase 2 study results are indicative of the results in future studies; the timing of completion and results of the Phase 3 studies for HTX-011; the timing of the NDA filing for HTX-011; and other risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

i Emend [aprepitant] capsules [US package insert] (Rev. May 2017).
ii Emend [fosaprepitant dimeglumine] for injection [US package insert] (Rev. August 2017).
iii Joerger, M. (2012). “Prevention and handling of acute allergic and infusion reactions in oncology.” Ann Oncol 23 Suppl 10: x313-319.
iv Leal, A. D., K. C. Kadakia, S. Looker, C. Hilger, K. Sorgatz, K. Anderson, A. Jacobson, D. Grendahl, D. Seisler, T. Hobday and C. L. Loprinzi (2014). “Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy.” Support Care Cancer 22(5): 1313-1317.
v Ottoboni, T., G. Boccia, M.R. Keller, M. Cravets, N. Clendeninn, B. Quart. “Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects.” Presented at Hematology/Oncology Pharmacy Association Annual Conference, March 29-April 1, 2017, Anaheim, CA.

Source: Heron Therapeutics, Inc.

Posted: November 2017

Related Articles:

Cinvanti (aprepitant) FDA Approval History

Tagged with:

About author

Related Articles